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Summary A series of 346 patients with primary operable breast cancer and a series of 145 patients with
advanced breast cancer were investigated for c-erbB-3 protein expression using the monoclonal antibody RTJ1.
Formalin-fixed, paraffin-embedded tumour samples were stained using a standard immunochemical method
and staining was assessed on a four-point scale. The study aimed to observe the expression of the c-erbB-3
protein and investigate any relationship between expression and established prognostic indicators and
prognosis. In both the primary and advanced series breast tumour tissue was found to stain heterogeneously
for c-erbB-3. The staining was observed to be predominantly cytoplasmic and the majority of tumours
exhibited moderate positivity. However, 15% and 35% of cases in the primary operable and advanced series
respectively displayed strong positive staining. No significant difference was found between the staining in the
primary and advanced series. In the primary operable breast cancers, no significant associations were
demonstrated with overall survival, disease-free interval, regional recurrence, the presence ofdistant metastases,
age, menopausal status, oestrogen receptor status, histological grade, lymph node stage, vascular invasion and
c-erbB-2 protein expression. However, a significant association was seen between the degree of c-erbB-3
immunoreactivity and both tumour size (P<0.01) and tumour type prognostic group (P=0.05). No overall
association with local recurrence was seen when the four groups of c-erbB-3 expression were analysed
(P =0.12), but when those tumours showing no or weak staining were compared with those showing moderate
and strong immunoreactivity it was seen that the latter were significantly more likely to develop local
recurrence (P=0.03). In the series of patients with advanced disease, no significant associations were
demonstrated with survival, UICC criteria, age, menopausal status, oestrogen receptor status, histological
grade, c-erbB-2 status or the presence of vascular invasion. In conclusion this study found variable expression
of c-erbB-3 protein in human breast carcinoma and an association with some recognised prognostic factors in
those patients with primary operable breast carcinoma. It seems, however, unlikely that c-erbB-3 protein
expression will emerge as a powerful enough prognostic factor to be of value in clinical practice.
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The c-erbB-3 gene is a recently identified member of the type
I family of growth factor receptors. It is located on
chromosome 12q13 and codes for a 180 000 molecular
weight glycoprotein. The protein product shows considerable
sequence homology to other members of the type I family of
growth factor receptors, the epidermal growth factor receptor
(EGFR) and the c-erbB-2 oncoprotein, especially in the
tyrosine kinase domain (Lemoine et al., 1992; Rajkumar et
al., 1993).
Expression of both EGFR and the c-erbB-2 oncoproteins
have been associated with established prognostic indicators
and a poorer prognosis in human breast carcinoma
(Sainsbury et al., 1985, 1987; Nicholson et al., 1990;
Grimaux et al., 1989; Walker et al., 1989; Wright et al.,
1989; Gullick et al., 1991; Slamon et al., 1987). The sequence
homology of the c-erbB-3 oncoprotein to the EGFR and c-
erbB-2 oncoprotein has lead to interest in c-erbB-3 expression
in breast cancer.
Using immunohistochemical techniques, c-erbB-3 expres-
sion in normal breast tissue has been shown to be weak to
moderate (Prigent et al., 1992). Expression in breast tumour
tissue is heterogeneous. However, overexpression, defined as
intensity greater than normal tissues, has been demonstrated
to occur in approximately 13 to 23% of cases (Lemoine et al.,
1992; Prigent et al., 1992) again using immunohistological
techniques.
Although associations have been found between high
expression of c-erbB-3, lymph node metastasis and c-erbB-2
expression, no other associations have been found with
established prognostic indicators or prognosis (Lemoine et
al., 1992; Gasparini et al., 1994). This study used the RTJ1
antibody for immunocytochemistry to investigate c-erbB-3
expression and the relationship between overexpression and
prognostic indicators and prognosis.
Methods
Patients
The patients in this study presented with primary operable or
advanced breast cancer to a single surgical team (RWB, JRF)
at the City Hospital, Nottingham. A total of 359 patients
with primary operable breast cancer and 155 patients with
advanced breast cancer were entered into the study. A small
number of cases with pure carcinoma in situ and those in
which insufficient tumour tissue was available for immuno-
histochemical assessment were excluded from the study
leaving 346 cases in the primary operable series and 145
cases in the advanced series.
Patients with primary operable disease were treated in a
standard fashion by simple or subcutaneous mastectomy or
tumour excision and radiotherapy. At the time of surgery,
nodes were sampled and the tumour staged as described
previously (Haybittle et al., 1982). Tumours were measured in
the fresh state in three perpendicular planes immediately after
excision. Fresh tumour blocks were snap frozen or fixed in
neutral buffered formalin and embedded in paraffin wax for
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further assay. Histological grade (Elston and Ellis, 1991),
tumour type (Ellis et al., 1992), oestrogen receptor status
(ER), vascular invasion (VI) (Pinder et al., 1994) and c-erbB-
2 status (Lovekin et al., 1991) were recorded for each tumour
sample. ER status was assessed in these patients by a
dextran-coated charcoal method and a cut-off of
10 fmol mg-' protein was used for analysis. For analysis of
tumour type four prognostic groups were used as described
previously (Pereira et al., 1995).
Patients were followed up after surgery at three monthly
intervals for 18 months and then every 6 months for 5 years,
then annually. The disease-free interval (DFI) was taken as
the time in months from the date of the primary treatment to
the first local, regional or distant recurrence. The overall
survival (OS) was taken as the time in months from the date
of the primary treatment to the time of death.
For the patients with advanced disease UICC criteria were
recorded as: 1, complete response; 2, partial response; 3,
static; 4, progression of disease. For analysis UICC criteria
1-3 were grouped and compared with those patients who
had progressive disease (category 4). In this group ofpatients
a cut-off of S fmol mg-' protein was considered positive for
ER analysis.
Immunohistochemistry
The tumour tissue was stained with a monoclonal IgM kappa
antibody, RTJ1, raised to a synthetic peptide from the
cytoplasmic domain of the human c-erbB-3 protein
(Rajkumar et al., 1993). A standard avidin-biotin immuno-
chemical technique was used. Sections (3 IM) were cut from
formalin-fixed, paraffin-embedded tumour samples, dewaxed
in xylene and taken to alcohol. Endogenous peroxidase
activity was blocked with hydrogen peroxide in methanol and
non-specific binding sites were blocked with swine serum.
Sections were incubated with the RTJ1 antibody at a 1:10
dilution. This dilution was shown to give optimal staining in
pilot experiments. Binding of the primary antibody was
demonstrated by a standard avidin-biotin complex techique;
biotinylated goat anti-mouse immunoglobulin followed by
preformed soluble complexes of avidin and biotinylated
horseradish peroxidase (Dako). Diaminobenzidine was used
as the chromogen with copper sulphate enhancement and
haematoxylin was used as the counterstain. Sections were
also processed in the absence of RTJ1 antibody to act as
negative controls and tumours of known c-erbB-3 immuno-
reactivity were stained as positive controls on each run.
Staining was assessed according to the degree of
cytoplasmic staining on a four-point scale: 0, negative; 1,
weakly positive; 2, moderately positive; 3, strongly positive.
Owing to heterogeneous immunoreactivity within most
sections, the whole tumour was systematically assessed by
grading fields every 0.2 cm within the section. If the tumour
area within the section was small or diffuse throughout the
stroma then the whole slide was scanned and graded. The
overall intensity for each tumour was taken to be that shown
by the majority of fields. Blind reassessment of a random
15% of the sections in each series ensured consistency in
assessment.
Adjacent normal breast epithelial tissue was also assessed.
Immunoreactivity in normal tissue was found to be
heterogeneous, and, if present, of weak or moderate
intensity. For the purpose of this study only those tumours
exhibiting strong positivity were considered to overexpress
c-erbB-3.
Statistical analysis
Relationships between variables were sought using chi-
squared analyses. Survival data were examined by the life-
table method (Mantel-Cox). All statistical analyses were
performed using SPSSX software.
Results
A variable degree of immunoreactivity was observed in breast
tumours. Within the carcinomas staining was found to be
heterogeneous and predominantly cytoplasmic with mem-
brane staining seen in less than 1% of cases (Figure 1). The
majority of tumours in both series exhibited moderate
immunoreactivity but a substantial proportion in both the
primary and advanced series exhibited strong positivity
(Figure 2). The cytoplasmic appearance of the stain varied
from finely granular to diffuse.
Primary operable breast cancer
Seventeen of the 346 sections (5%) in the primary series
showed no immunoreactivity with the RTJ1 antibody, 111
(32%) were weakly positive, 167 (48%) showed moderate
positivity and 51 (15%) were scored as showing strong
positivity.
Associations with other prognostic variables and survival
are shown in Table I. No correlation was found between
c-erbB-3 overexpression and OS, DFI or regional recurrence,
age, menopausal status, ER status, histological grade, lymph
node stage, the presence ofdistant metastases, VI and c-erbB-
2 protein expression.
An association was seen between the intensity of c-erbB-3
immunostaining with the RTJ1 antibody and factors
indicative of poor prognosis in this series of patients with
primary operable breast cancer. A trend was seen between
c-erbB-3 immunostaining and tumour type group (P=0.05);
patients in the poor prognostic type group more often
showed moderate or strong staining, whereas tumours of
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Figure 1 An invasive adenocarcinoma of the breast showing benign mammary duct. The tumour cells show intense c-erbB-3
positive immunoreactivity for c-erbB-3 of varying intensities of all reactivity. There is very mild heterogeneous reactivity in the
tumour cells. normal luminal epithelial and myoepithelial cells.
230Table I Associations of c-erbB-3 immunostaining (none, weak;
moderate or strong) with other prognostic factors, survival and
recurrence in patients with primary operable breast carcinoma
Factor Cut off Chi-squared P
Age <30, 31-40, 41-50, 7.0 0.86
51 -60, >60 years
Menopausal status 7.9 0.25
ER status 10 fmol mg-l protein 6.9 0.07
Histological grade 1, 2, 3 11.0 0.28
Lymph node stage 1, 2, 3 12.4 0.19
Size <2, 2.1 -5.0, >5.0 cm 18.4 <0.01
Local recurrence 5.76 0.12
Regional recurrence 6.5 0.37
Distant metastases 4.5 0.22
C-erbB-2 Membrane 4.0 0.26
immunoreactivity
VI None, probable, definite 8.4 0.21
Tumour type 1, 2, 3, 4a 16.9 0.05
OS Overall statistic (3 d.f.) 0.2 0.98
DFI Overall statistic (3 d.f.) 4.0 0.26
aSee Pereiraet al., 1995.
excellent prognosis more commonly showed weak immuno-
reactivity. In addition an association was seen with tumour
size (P<0.01); primary breast tumours larger than 2 cm in
size showed a tendency to be more frequently moderately or
strongly positive for c-erbB-3. These associations with
tumour size and type were not found if c-erbB-3 was
grouped into two categories as negative or positive (weak,
moderate or strong) when P-values were 0.68 and 0.37
respectively.
Information on local recurrence of disease was available
on 323 patients of whom 77 had local recurrence of breast
carcinoma. Although no overall relationship between
c-erbB-3 immunostaining and local recurrence of disease
was identified when tumours were analysed in the four
groups of immunoreactivity (P=0.12), a correlation between
degree of immunoreactivity and local recurrence was seen
when those tumours showing no or only weak immunostain-
ing were compared with those showing moderate and strong
reactivity. A total of 56 of the 77 patients with local
recurrence of disease (72.7%) had tumours which stained
moderately or strongly with the RTJ1 antibody compared
with 144 of the 246 (58.5%) with no evidence of locally
recurrent carcinoma (P=0.03).
Advanced breast cancer
Two of the 145 sections (1%) in the advanced series showed
no immunostaining, 32 (22%) were classed as weakly
positive, 61 (42%) showed moderate positivity and 50
(35%) were categorised as strongly positive.
No associations were demonstrated between c-erbB-3
overexpression and age, menopausal status, ER status,
histological grade, c-).
Discussion
There has been considerable interest in the amplification or
regulation of members of the type I family of tyrosine kinase
growth factor receptors in human breast carcinoma. The first
member of the family, epidermal growth factor receptor
(EGFR), a 170 kDa transmembrane glycoprotein, has been
shown to play a role in normal breast development and
differentiation. Overexpression of EGFR in human breast
carcinoma was associated with a poor prognosis by Sainsbury
et al. (1987). Relapse-free survival and OS were found to be
significantly decreased in EGFR-positive tumours. This
association with a poor prognosis has been suggested by
many studies. EGFR expression has also been correlated with
established prognostic indicators, with an important inverse
C-erbB-3 in human breast carcinoma
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Table II Associations of c-erbB-3 immunostaining with other
prognostic factors and with survival in patients with advanced
breast cancer
Stages III and IV
Chi-
Factor Cut off squared P
Age <40, 41-61, >61 years 1.4 0.49
Menopausal <0.1 1.00
status
ER status 5 fmol mg- protein <0.1 0.99
Histological 1, 2, 3 1.3 0.52
grade
C-erbB-2 Membranous reactivity <0.1 0.92
positive
VI None, probable or definite 1.3 0.53
Survival 0.2 0.68
UICC categories 1, 2, 3 vs 4 <0.1 0.79
relationship between EGFR and ER status. This suggests a
possible role for EGFR in the treatment of breast cancer as
well as a prognostic indicator (Sainsbury et al., 1985, 1987;
Nicholson et al., 1990).
The second member of the family, c-erbB-2 is a 185 kDa
transmembrane glycoprotein. Comparative molecular and
immunohistological studies have demonstrated an associa-
tion between amplification of the c-erbB-2 gene and strong
cell membrane immunoreactivity for the protein in some solid
human tumours and, in particular, human breast carcinoma.
Such amplification of the gene, detected either by molecular
investigation or through immunocytochemical demonstration
of membrane protein has, in large studies examining large
series of breast cancers, been shown to be associated with a
poorer prognosis. In 1987, Slamon et al. carried out an initial
study that demonstrated a significant relationship between
c-erbB-2 immunoreactivity and a shorter DFI and OS
(Slamon et al., 1987). Further studies have supported this
association (Wright et al., 1989; Gullick et al., 1991; Lovekin
et al., 1991). An inverse association has also been
demonstrated between c-erbB-2 expression and ER status
(Slamon et al., 1987).
The c-erbB-3 gene was first cloned by Kraus et al. in 1989
and subsequently by Plowman et al. in 1990. Its protein
product is a 180 kDa transmembrane glycoprotein that shows
considerable sequence homology to the EGFR and the
c-erbB-2 protein, especially in the tyrosine kinase domain.
A study examining c-erbB-3 protein expression in normal
human adult and fetal tissues demonstrated that most
developing human tissues, except haemopoietic tissues,
express c-erbB-3 and expression is not restricted to
proliferating cells. Normal adult breast tissue shows a
moderately intense staining of luminal epithelial cells of
breast acini and a weaker reactivity of basal myoepithelial
cells. This normal distribution is distinctive and different
from that observed with EGFR and c-erbB-2. Reactivity is
predominantly cytoplasmic and no membrane reactivity of
normal tissue has been observed in these early studies
(Prigent et al., 1992).
Poller et al. used a polyclonal antibody raised to the
c-erbB-3 protein to examine c-erbB-3 expression in a variety
of adenocarcinomas. C-erbB-3 protein expression was
detected in a series of 13 out of 14 primary breast
carcinomas. Expression of the c-erbB-3 protein was found
to be a common event in adenocarcinomas but its role in
neoplastic progression remained unclear (Poller et al., 1992).
In a more detailed study of breast carcinoma, Lemoine et
al. (1992) showed consistently higher levels of the c-erbB-3
oncoprotein in cell lines but a wide range of expression in
resected primary human breast tumours. In the breast
tumours overexpression was seen in 22% of cases, the
predominant pattern being cytoplasmic with membrane
immunoreactivity being seen in one case only. Investigation
of associations with tumour size, histological grade, stage andC-erbB-3 i human breast carcioma
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survival showed correlation only with lymph node metastatic
disease. No relationship with overall prognosis was demon-
strated.
In our series. using the IgM monoclonal antibody RTJ1
(Rajkumar et al.. 1993). we have examined the largest series of
patients presenting with breast carcinoma to date, including
346 patients with primary operable breast cancer and 145
patients with advanced disease. Cytoplasmic reactivity was the
predominant pattern seen and less than 1% of tumours
showed positive membrane reactivity. As previously demon-
strated by Lemoine et al.. the degree of expression varied
(Lemoine et al.. 1992). The majority of tumours expressed
moderate immunoreactivity. Fifteen percent and 35% ofcases
in the primary and advanced series respectively demonstrated
strong positive staining which for the purposes of this study
was considered overexpression. as reactivity in normal breast
epithelial tissue. although heterogeneous. was confined to
negative. weak or moderate levels of intensity. Different levels
of frequency of overexpression were identified in the two
groups of patients in this study but this failed to reach
statistical significance.
No significant associations were demonstrated between
c-erbB-3 expression and survival in either patients with
primary operable breast cancer or those with advanced
disease and no correlation with DFI was found in the former
group. In particular there was no relationship with lymph
node status in this series which is in contrast to the study
carried out by Lemoine et al. (1992). In the patients with
operable disease. however, an association was seen between
greater intensities of immunoreactivity with RTJ1 antibody
and both increased tumour size and a weaker association
with poor prognostic type group. In addition those tumours
which showed moderate or strong immunoreactivity with
c-erbB-3 antibody appeared to be more likely to develop
locally recurrent disease. The associations we report here
have not been previously documented. Nevertheless, it seems
unlikely that immunohistochemical assessment of c-erbB-3
expression will provide sufficiently powerful prognostic
information to be clinically useful: the associations with
other prognostic factors we describe here are based on
differences in intensity of immunoreactivity rather than
presence or absence of staining.
A recent study has demonstrated that the growth factor
ligand heregulin binds to the c-erbB-3 receptor (Carraway et
al.. 1994). The same group have also demonstrated little or
no tyrosine kinase activity following stimulation and binding
of heregulin with the c-erbB-3 receptor. However, in cells
expressing both c-erbB-2 and c-erbB-3 a high-affinity binding
site is generated and on stimulation produces unique tyrosine
residues (Sliwkowski et al.. 1994). This is in contrast to the
interaction and complex formation between c-erbB-2 and c-
erbB-4 where both receptors have active tyrosine kinase
components which are capable of autophosphorylation
(Plowman et al., 1993). The potential for type I tyrosine
kinase receptors to produce different combinations of
heregulin-stimulated heterodimeric complexes could explain
some of the varied biological activities that have been
demonstrated with this group of receptors (Carraway and
Cantley, 1994). We have found no association between
overexpression of c-erbB-2 and c-erbB-3 assessed immuno-
histochemicallv.
In common with other published series we have
demonstrated virtually ubiquitous cytoplasmic expression of
c-erbB-3 protein at weak to strong levels. The c-erbB-3 gene
sequence codes for transmembrane types of protein but
membrane localisation of c-erbB-3 protein appears to be a
rare phenomenon and is much lower in frequency than
EGFR and c-erbB-2 proteins in invasive breast cancer. It is
known that EGFR and c-erbB-2 are internalised by
endocytosis after ligand binding. The predominant cytoplas-
mic localisation of c-erbB-3 protein could indicate inter-
nalised. non-functional or non-membrane-associated protein.
The c-erbB-3 protein may be an orphan receptor (Kraus et
al.. 1993) but, if the parent of the orphan in terms of
signalling were c-erbB-2 or c-erbB-4 as has recently been
suggested. then the c-erbB-3 protein may be an important
cofactor in the biological effects of type I growth factor
receptors.
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